Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies
Rhea-AI Summary
Senti Biosciences (Nasdaq: SNTI) announced a Cell Systems publication (April 1, 2026) describing a systematic framework for NOT-gated CAR circuits in T and NK cells. The study tested more than 60 CAR circuit designs, identified LIR1-based inhibitory CARs as potent regulators, and showed selective tumor killing with reduced exhaustion and preserved cytotoxicity in vitro and in vivo, supporting portability across CAR T and CAR NK modalities and the Gene Circuit platform. A patent application covering aspects of the technology has been filed.
AI-generated analysis. Not financial advice.
Positive
- Evaluated >60 CAR designs for quantitative design principles
- LIR1 inhibitory CARs identified as particularly potent regulators
- Reduced cellular exhaustion with preserved cytotoxicity after repeated antigen exposure
- Portability across T and NK cells shown in vitro and in vivo xenograft models
- Patent application filed covering aspects of the NOT-gated CAR technology
Negative
- None.
News Market Reaction – SNTI
On the day this news was published, SNTI gained 3.31%, reflecting a moderate positive market reaction. Argus tracked a peak move of +13.2% during that session. Argus tracked a trough of -7.1% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $888K to the company's valuation, bringing the market cap to $27.72M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SNTI gained 5.21%, while momentum scan shows only two biotech peers (RANI, ANTX) moving up without news and no tracked peers moving in the same direction as SNTI. This points to a stock-specific reaction to the logic-gated CAR publication rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 27 | Earnings and update | Negative | -10.4% | Reported 2025 financial results with significant net loss and limited cash. |
| Mar 23 | Clinical data preview | Positive | -2.2% | Announced upcoming SENTI-202 clinical and translational data presentations. |
| Mar 03 | Conference presentation | Neutral | +2.1% | CEO presentation at Leerink Partners 2026 Global Healthcare Conference. |
| Feb 24 | Conference presentation | Neutral | +7.1% | Participation in TD Cowen 46th Annual Health Care Conference. |
| Feb 20 | Industry event | Neutral | -3.4% | Presented Gene Circuit platform and SENTI-202 at Cell & Gene Live event. |
Recent SNTI news often produced mixed reactions, with some clinically oriented or conference updates sold into, but negative financials aligned with a downside move.
Over the past months, Senti Biosciences has focused investor attention on its Gene Circuit and SENTI‑202 programs. On Feb 20 and Feb 24, the company highlighted its platform and pipeline at industry conferences, followed by additional conference and corporate presentations in early March. The Mar 27 earnings and corporate update underscored ongoing losses and cash constraints. Today’s Cell Systems publication extends this narrative by providing peer‑reviewed validation of logic‑gated CAR design, complementing prior positive SENTI‑202 clinical and mechanistic data communications.
Market Pulse Summary
This announcement highlighted peer-reviewed validation of Senti’s logic-gated CAR design, showing NOT-gated circuits in T and NK cells that improved tumor–healthy cell discrimination and durability across more than 60 designs. It reinforced the role of the Gene Circuit platform in advancing SENTI‑202 and related programs. Investors may track how this foundational work supports future clinical data, partnership discussions, and updates on cash resources and development priorities.
Key Terms
not-gated chimeric antigen receptor medical
car medical
t cells medical
natural killer (nk) cells medical
synthetic biology medical
lir1 receptor medical
xenograft model medical
gene circuit platform medical
AI-generated analysis. Not financial advice.
SOUTH SAN FRANCISCO, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the publication of new peer-reviewed research in Cell Systems demonstrating its systematic framework for engineering NOT-gated chimeric antigen receptor (CAR) circuits in both T cells and natural killer (NK) cells. The study demonstrates how Logic-Gated receptor designs can significantly improve the efficacy, precision, and safety of cell therapies by enabling immune cells to selectively eliminate tumor cells while sparing healthy tissue. This foundational paper complements Senti’s recent announcements on positive clinical data with its Logic-Gated SENTI-202 product in the treatment of relapsed/refractory Acute Myeloid Leukemia presented at the 2025 American Society for Hematology Annual Meeting.
The paper, titled “NOT-gated Chimeric Antigen Receptor Circuits in T and NK Cells,” presents a comprehensive evaluation of dual-receptor CAR circuits that integrate an activating CAR (for cancer killing) with an inhibitory CAR (for healthy cell protection). By quantitatively analyzing more than 60 CAR circuit designs, the study defines core design principles that govern activation strength, inhibition dynamics, antigen dose response and functional durability across immune cell types.
“This study highlights the power of synthetic biology to introduce decision-making into living medicines,” said Tim Lu, M.D., Ph.D., Chief Executive Officer and Co-Founder of Senti Biosciences. “By systematically dissecting the interaction between activating and inhibitory CARs, we provide a roadmap for building immune cells that are both effective and precise.”
The study identifies inhibitory CARs based on the LIR1 receptor as particularly potent regulators of immune cell activity, outperforming several canonical immune checkpoint receptors. In T cells, optimized NOT-gated CAR circuits not only improved discrimination between tumor and healthy cells but also reduced markers of cellular exhaustion and preserved cytotoxic killing of cancer cells following repeated antigen exposure. These findings suggest that inhibitory CAR signaling can provide benefits beyond target specificity, potentially improving the durability of therapeutic responses.
“These results show that inhibitory CARs have very interesting and underappreciated properties that can improve the performance of immune cell therapies,” said Wilson Wong, Ph.D., Professor of Biomedical Engineering at Boston University, and Scientific Co-Founder of Senti.
Importantly, the authors demonstrate that many NOT-gated CAR designs exhibited high performance in both T cells and NK cells. In an in vivo mixed-cell xenograft model, NOT-gated CAR T cells and CAR NK cells selectively eliminated tumor cells while sparing off-tumor cells expressing protective antigens. These results highlight the portability of logic-gated CAR circuits across ex vivo and in vivo CAR modalities, and their potential to treat cancers where clean tumor-specific targets are unavailable.
The findings further support the applicability of Senti Biosciences’ Gene Circuit platform to cell and gene therapy, which is designed to program cells with logic-based control over therapeutic activities. NOT-gated CAR circuits represent a foundational approach for enhancing safety and expanding the therapeutic window of engineered immune cells in cancer and other diseases. A patent application has been filed covering aspects of the technology described in the study.
The full article is now available online in Cell Systems.
About Senti Bio
Senti Bio is a clinical stage biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline comprises cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.
Availability of Other Information About Senti Biosciences, Inc.
For more information, please visit the Senti Bio website at www.sentibio.com or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
SNTI@jtcir.com
